

PERSONAL INFORMATION

Cristina Migali

WORK EXPERIENCE

October 2019–Present

Scientific Advice Working Party (SAWP) - Alternate Member
European Medicine Agency (Netherlands)

March 2016–Present

Clinical Assessor (oncology)
Italian Medicines Agency (AIFA) (Italy)
Innovation and Pharmaceutical Strategy Division

Clinical assessor in centralized marketing authorization procedures and scientific advice procedures for oncologic products

April 2015–February 2016

Medical Oncologist
European Institute of Oncology - IEO (Italy)
New Drugs and Early Drug Development for Innovative Therapies Unit
Management of cancer patients enrolled in Early Phase clinical trials, with a focus on breast cancer

October 2014–March 2015

Clinical Research Fellow
The Royal Marsden Hospital (United Kingdom)
Drug Development Unit
Management of cancer patients enrolled in Phase I Clinical Trials

September 2012–February 2014

Honorary Clinical Fellow
The Royal Marsden Hospital (United Kingdom)
Gynaecology, Renal/Melanoma and Lung Units

June 2009–July 2014

Resident in Medical Oncology
University of Siena (Italy)

EDUCATION AND TRAINING

2009–2014

Specialist training programme in Medical Oncology
University of Siena (Italy)

2002–2008

Doctor of Medicine (MD)
University of Siena (Italy)

ADDITIONAL INFORMATION

Expertise

Oncology
Clinical trials
Centralized procedure

Publications

■ Porcu M, Solinas C, **Migali C**, Battaglia A, Schena M, Mannelli L, Addeo A, Willard-Gallo K, Saba

- L. Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review. *Target Oncol.* 2020 Jan 11.
- Dolly SO, **Migali C**, Tunariu N, Della-Pepa C, Khakoo S, Hazell S, de Bono JS, Kaye SB, Banerjee S. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. *ESMO Open.* 2017 Apr 12;2(1):e000101.
 - George A, McLachlan J, Tunariu N, Della Pepa C, **Migali C**, Gore M, Kaye S, Banerjee S. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. *BMC Cancer.* 2017 Jun 30;17(1):456.
 - **Migali C**, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Adv Med Oncol.* 2016 Sep;8(5):360-74.
 - **Migali C**, Bielinska AM, Bhosle J, O'Brien M. Development in the diagnostic lung cancer pathway: implication for treatment. *Lung Cancer Management.* 3(5):417-28.
 - Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, **Migali C**, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R. Effects of Intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. *Int J Clin Oncol.* 2011 Jan 18.
 - Licchetta A, Correale P, **Migali C**, Remondo C, Francini E, Pascucci A, Magliocca A, Guarnieri A, Savelli V, Piccolomini A, Carli AF, Francini G. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. *J Chemother* 2010 Jun;22(3):201-4.
 - Correale P, Remondo C, Carbone SF, Ricci V, **Migali C**, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong anti tumor activity in advanced non-small-cell-lung cancer patients. *Cancer Biology & Therapy* 2010 May 1;9(9):1-9.
 - Correale P, Marra M, Remondo C, **Migali C**, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, Caraglia M. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). *Eur J Cancer* 2010 Apr 15.
 - Correale P, Rotundo MS, Del Vecchio MT, Remondo C, **Migali C**, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, Tassone P, Francini G, Tagliaferri P. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. *J Immunother.* 2010 Apr 8.
 - Montagnani F, **Migali C**, Fiorentini G. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point? *J Clin Oncol.* 2009 Oct 1;27(28):e132-3.
 - Correale P, Miano S, Remondo C, **Migali C**, Rotundo MS, Macri P, Tagliaferri P, Tassone P, Caraglia M, Gotti G, Francini G. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. *Cancer Biology & Therapy* 2009 March 15;8(6):1-6.

Projects

Memberships

European Society of Medical Oncology (ESMO)

Other Relevant Information